Clinical Applications of Nucleic Acid Aptamers in Cancer

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2014 Apr 29

PMID 24772298

Citations 17

Authors

Xiaoyu Pei

Jun Zhang

Jie Liu

Affiliations

Soon will be listed here.

Abstract

Nucleic acid aptamers are small single-stranded DNA or RNA oligonucleotide segments, which bind to their targets with high affinity and specificity via unique three-dimensional structures. Aptamers are generated by an iterative selection process, termed as systematic evolution of ligands by exponential enrichment. Owing to their specificity, non-immunogenicity, non-toxicity, easily modified chemical structure and wide range of targets, aptamers appear to be ideal candidates for various clinical applications (diagnosis or treatment), such as cell detection, target diagnosis, molecular imaging and drug delivery. Several aptamers have entered the clinical pipeline for applications in diseases such as macular degeneration, coronary artery bypass graft surgery and various types of cancer. The aim of this review was to summarize and highlight the clinical applications of aptamers in cancer diagnosis and treatment.

Citing Articles

Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.

Ghaedrahmati F, Esmaeil N, Abbaspour M Cancer Commun (Lond). 2022; 43(2):177-213.

PMID: 36585761 PMC: 9926962. DOI: 10.1002/cac2.12394.

Aptamer-Based Probes for Cancer Diagnostics and Treatment.

Hu X, Zhang D, Zeng Z, Huang L, Lin X, Hong S Life (Basel). 2022; 12(11).

PMID: 36431072 PMC: 9695321. DOI: 10.3390/life12111937.

Antiproliferative Effects of the Aptamer d(GGGT) and Its Analogues with an Abasic-Site Mimic Loop on Different Cancer Cells.

Virgilio A, Pecoraro A, Benigno D, Russo A, Russo G, Esposito V Int J Mol Sci. 2022; 23(11).

PMID: 35682635 PMC: 9181107. DOI: 10.3390/ijms23115952.

FRET-Based Aptasensor for the Selective and Sensitive Detection of Lysozyme.

Sapkota K, Dhakal S Sensors (Basel). 2020; 20(3).

PMID: 32050422 PMC: 7038949. DOI: 10.3390/s20030914.

Utilizing Peptide Ligand GPCRs to Image and Treat Pancreatic Cancer.

Matters G, Harms J Biomedicines. 2018; 6(2).

PMID: 29865257 PMC: 6027158. DOI: 10.3390/biomedicines6020065.

References

Wessels J, Busse A, Mahrt J, Dullin C, Grabbe E, Mueller G . In vivo imaging in experimental preclinical tumor research--a review. Cytometry A. 2007; 71(8):542-9. DOI: 10.1002/cyto.a.20419. View

Tuerk C, Gold L . Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990; 249(4968):505-10. DOI: 10.1126/science.2200121. View

Cheng J, Teply B, Sherifi I, Sung J, Luther G, Gu F . Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2006; 28(5):869-76. PMC: 2925222. DOI: 10.1016/j.biomaterials.2006.09.047. View

Chen X, Estevez M, Zhu Z, Huang Y, Chen Y, Wang L . Using aptamer-conjugated fluorescence resonance energy transfer nanoparticles for multiplexed cancer cell monitoring. Anal Chem. 2009; 81(16):7009-14. DOI: 10.1021/ac9011073. View

Mannironi C, Scerch C, Fruscoloni P, Tocchini-Valentini G . Molecular recognition of amino acids by RNA aptamers: the evolution into an L-tyrosine binder of a dopamine-binding RNA motif. RNA. 2000; 6(4):520-7. PMC: 1369933. DOI: 10.1017/s1355838200991763. View

Mallikaratchy P, Stahelin R, Cao Z, Cho W, Tan W . Selection of DNA ligands for protein kinase C-delta. Chem Commun (Camb). 2006; (30):3229-31. DOI: 10.1039/b604778e. View

Davis K, Abrams B, Lin Y, Jayasena S . Use of a high affinity DNA ligand in flow cytometry. Nucleic Acids Res. 1996; 24(4):702-6. PMC: 145686. DOI: 10.1093/nar/24.4.702. View

Rosi N, Giljohann D, Thaxton C, Lytton-Jean A, Han M, Mirkin C . Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science. 2006; 312(5776):1027-30. DOI: 10.1126/science.1125559. View

Wang L, Tan W . Multicolor FRET silica nanoparticles by single wavelength excitation. Nano Lett. 2006; 6(1):84-8. PMC: 2527125. DOI: 10.1021/nl052105b. View

10.

Shu D, Guo P . A viral RNA that binds ATP and contains a motif similar to an ATP-binding aptamer from SELEX. J Biol Chem. 2002; 278(9):7119-25. DOI: 10.1074/jbc.M209895200. View

11.

Nieuwlandt D, Wecker M, Gold L . In vitro selection of RNA ligands to substance P. Biochemistry. 1995; 34(16):5651-9. DOI: 10.1021/bi00016a041. View

12.

Tang Z, Shangguan D, Wang K, Shi H, Sefah K, Mallikratchy P . Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem. 2007; 79(13):4900-7. DOI: 10.1021/ac070189y. View

13.

Nimjee S, Rusconi C, Harrington R, Sullenger B . The potential of aptamers as anticoagulants. Trends Cardiovasc Med. 2005; 15(1):41-5. DOI: 10.1016/j.tcm.2005.01.002. View

14.

Medley C, Smith J, Tang Z, Wu Y, Bamrungsap S, Tan W . Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells. Anal Chem. 2008; 80(4):1067-72. DOI: 10.1021/ac702037y. View

15.

Shangguan D, Li Y, Tang Z, Cao Z, Chen H, Mallikaratchy P . Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A. 2006; 103(32):11838-43. PMC: 1567664. DOI: 10.1073/pnas.0602615103. View

16.

Kang W, Chae J, Cho Y, Lee J, Kim S . Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers. Small. 2009; 5(22):2519-22. DOI: 10.1002/smll.200900848. View

17.

Klug S, Famulok M . All you wanted to know about SELEX. Mol Biol Rep. 1994; 20(2):97-107. DOI: 10.1007/BF00996358. View

18.

Hofmann H, Limmer S, Hornung V, Sprinzl M . Ni2+-binding RNA motifs with an asymmetric purine-rich internal loop and a G-A base pair. RNA. 1997; 3(11):1289-300. PMC: 1369568. View

19.

Blagosklonny M . Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle. 2004; 3(8):1035-42. View

20.

Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H . Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biol Ther. 2003; 1(6):646-51. DOI: 10.4161/cbt.314. View